Contribute Try STAT+ Today

A small biotech firm, Humanigen, said Monday that its experimental drug reduced the risk of patients hospitalized with Covid-19 being put on ventilators.

Shares in the company rose 86% on the news, and Humanigen said it would ask the Food and Drug Administration to grant an emergency use authorization based on the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hold on a moment. One internal trial of 517 patients leads to positive press and an EUA.

    Meanwhile the safe, unpatented drug Ivermectin now has 48 independent studies reporting positive results against all stages of covid19 (including as a prophylactic), 25 of which were RCT’s. It’s been adopted in much of the World outside the US sphere of influence, strongly correlating with some astonishing reductions in excess mortalities. Yet the FDA has, without reviewing any data, recommended against its use.

    Make no mistake – our institutions aren’t interested in solutions. There is far too much money to be made, whatever the human cost.

    Top-of-the-morning to you to.

Comments are closed.